News & Updates
Showing Hepatology articles
Showing

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening
Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.

Targeted HCV microelimination programme expanded after initial success
The University of Hong Kong’s (HKU) hepatitis C virus (HCV) microelimination programme targeting high-risk populations is expanded recently to eligible persons in custody (PICs) following initial success in individuals with history of illicit drug use, needle sharing or imprisonment undergoing rehabilitation in halfway houses or drug rehabilitation centres.

Vaccines protect liver disease patients against severe COVID-19
Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.

HCC incidence rare in autoimmune hepatitis, tied to obesity, cirrhosis
The incidence of hepatocellular carcinoma (HCC) remains low in patients with autoimmune hepatitis (AIH) even after developing cirrhosis, according to a study. Factors such as obesity, cirrhosis, and AIH/primary sclerosing cholangitis (PSC) variant syndrome can increase the risk of HCC incidence.



